NightHawk Biosciences(US:NHWK)2024-05-28 21:28Revenue and Expenses - For the three months ended March 31, 2024, the company recognized $3.5 million in process development revenue, a significant increase from $0.7 million in the same period of 2023, attributed to expanded biomanufacturing operations [155]. - Cost of revenues for the three months ended March 31, 2024, was $0.9 million, up from $0.6 million in 2023, primarily due to increased service offerings and milestone work on multiple contracts [156]. - Research and development expenses decreased to $3.9 million for the three months ended March 31, 2024, down from $6.3 million in 2023, with a notable reduction in unallocated expenses [157]. - Selling, general and administrative expenses were $5.0 million for the three months ended March 31, 2024, compared to $6.5 million in 2023, reflecting a decrease in marketing and consultant costs [159]. Net Loss and Deficit - The company reported a net loss of $4.7 million for the three months ended March 31, 2024, compared to a net loss of $12.9 million for the same period in 2023 [163]. - The company has an accumulated deficit of approximately $258.8 million as of March 31, 2024, up from $254.4 million at the end of 2023 [163]. - The company has an accumulated deficit of $258.8 million through March 31, 2024, and has incurred negative cash flows from operations since its inception [172]. Cash Flow and Financing - As of March 31, 2024, the company had approximately $1.7 million in cash and cash equivalents, not including the net proceeds of $5.3 million raised in a recent public offering [162]. - The company reported a net cash used in operating activities of $4.7 million for the three months ended March 31, 2024, a decrease of $9.1 million compared to $13.8 million in the same period of 2023 [168]. - Net cash provided by investing activities was $2.8 million during the three months ended March 31, 2024, down from $13.5 million in the same period of 2023, primarily due to decreased sales of short-term investments [169]. - The company generated $3.3 million in net cash from financing activities during the three months ended March 31, 2024, compared to a net cash used of $0.3 million in the same period of 2023 [170]. - The company had approximately $5.6 million in cash and cash equivalents and short-term investments as of May 17, 2024 [167]. - The company is considering multiple alternatives for financing, including additional equity financings and collaborations, to meet its capital needs [167]. - The company may need to delay, reduce, or terminate operations if it cannot raise additional funds or engage a strategic partner [167]. Future Outlook and Concerns - The company anticipates significant commercialization expenses related to its CDMO business and will require substantial additional funding for its manufacturing facility operations [164]. - The company expects to incur significant commercialization expenses related to its Scorpius manufacturing facility operations [172]. - There is substantial doubt about the company's ability to continue as a going concern within one year after the financial statements are available to be issued [167]. - The company is no longer eligible to sell securities under its Registration Statement on Form S-3 until June 2025 due to late filings [166]. - The company has initiated a restructuring plan to reduce operating costs and refocus on its CDMO services, which includes marketing non-core assets [162]. Public Offering - On May 16, 2024, the company completed a public offering resulting in gross proceeds of approximately $6.0 million [141].